Here we give the stock returns of the constituents in both our Canadian Cannabis LPs Portfolio (designated with a *) and the American Cannabis MSOs Portfolio in May, in descending order, and this week, the Adj. EBITDA as a % of Net Revenue for each constituents – the higher the better – which is very helpful in determining the value of a company as compared to its peers and their latest quarterly financial reports (links provided):
- Adj. EBITDA of (42.2)% of Net Revenue
- Cronos Q1 Financial Metrics Show Improvement
- Adj. EBITDA of (0.3)% of Net Revenue
- Organigram Q2 Financial Metrics Mixed
- Adj. EBITDA of 35.7% of Net Revenue
- Net Profit of: 11.3% of Net Revenue
- Green Thumb Q1 Financial Metrics Excel Across The Board
- Adj. EBITDA of 22.6% of Net Revenue
- Curaleaf Reports 16% Reduction In Net Loss In Q1
- Adj. EBITDA of 28.8% of Net Revenue
- All Cresco Labs’ QI Financial Metrics Down Except SG&A
- Adj. EBITDA of 3.4% of Net Revenue
- Tilray’s Q3 Financials Disappoint
- Adj. EBITDA of 20.1% of Net Revenue
- TerrAscend Reports 64% Reduction In Net Loss In Q1 Financial Report
- Adj. EBITDA of 35.5% of Net Revenue
- Trulieve Cannabis Q1 Financial Results Impressive
- Adj. EBITDA of 3.4% of Net Revenue
- Aurora Cannabis Q3 Financials Unimpressive
- Adj. EBITDA of 30.3% of Net Revenue
-
Verano Q1 Financial Metrics Down Across The BoardAyr Wellness (AYRWF): down 34.9% in May (down 2.6% this week)
- Adj. EBITDA of 24.7% of Net Revenue
- AYR Wellness’ Q1 Financials Reveal 94% Reduction In Net Loss
- Adj. EBITDA of (20.7)% of Net Revenue
- Cannabis Growth Q4 Financials Unimpressive
SummaryThe above 12 stocks are down 3.3%, on average, this week and are down 31.2%, on average, since the beginning of May but are up 24.0% YTD. More By This Author:
